Edgewise Therapeutics, Inc. (EWTX)

Edgewise Therapeutics' stock has experienced significant movement, with a 52-week range between $12.15 and $39.96. In March 2026, positive safety data for EDG-7500 in HCM led to a 20% share surge. Also in March 2026, positive long-term results for sevasemten in Becker muscular dystrophy were reported. Early 2026 was characterized as potentially transformative due to upcoming catalysts. In May 2026, the company reported its Q1 2026 earnings, with a net loss of $49.0 million, beating analyst estimates for EPS. Several research firms have reiterated or raised their price targets and ratings for EWTX.

As a clinical-stage biopharmaceutical company, Edgewise Therapeutics does not have commercialized products, so demand seasonality does not apply. The company's financial health is tied to the success of its clinical trials and regulatory approvals rather than product sales.

Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing orally administered small-molecule therapies for severe, rare neuromuscular and cardiac disorders. Their lead product candidate, sevasemten (EDG-5506), is in late-stage clinical trials for dystrophinopathies like Duchenne and Becker muscular dystrophy. The company is also advancing EDG-7500 for hypertrophic cardiomyopathy and EDG-15400 for heart failure with preserved ejection fraction.

Edgewise Therapeutics, Inc. is headquartered in Boulder, Colorado. While its primary operations are in the United States, the company is preparing for global clinical trials and aims to establish collaborations and partnerships to facilitate broader patient access.

Edgewise Therapeutics' brand reputation appears positive, driven by promising clinical trial results and strong analyst sentiment. Positive clinical trial data for sevasemten and EDG-7500 has bolstered confidence in the company's pipeline. The company's communication of 2026 as a "transformative year" has generated investor excitement. Consistent "Moderate Buy" consensus rating from analysts indicates a favorable view of the company's prospects.

Institutional investors hold a significant portion of Edgewise Therapeutics' outstanding shares, approximately 92% as of Q1 2025. Major institutional owners include OrbiMed Advisors, RA Capital Management, L.P., Viking Global Investors, BlackRock, Inc., Baker Bros. Advisors LP, Cormorant Asset Management, Janus Henderson Group, Novo Holdings A/S, and The Vanguard Group Inc. Individual insider ownership was approximately 4.2% as of Q1 2025.